A Randomized, Double Blind, Placebo Controlled, Multicenter, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of HTD1801 in Adults With Hypercholesterolemia
Latest Information Update: 07 Mar 2023
At a glance
- Drugs Berberine ursodeoxycholate (Primary)
- Indications Hypercholesterolaemia
- Focus Adverse reactions
- Sponsors HighTide Biopharma
- 29 Aug 2020 Results presented at The International Liver Congress 2020
- 09 Jan 2019 Status changed from recruiting to completed.
- 22 Feb 2018 Status changed from not yet recruiting to recruiting.